Add office photos
Employer?
Claim Account for FREE
Aurobindo Pharma
4.0
based on 5.3k Reviews
Video summary
Proud winner of ABECA 2025 - AmbitionBox Employee Choice Awards
Company Overview
Associated Companies
Company Locations
Working at Aurobindo Pharma
Company Summary
Global leader in the pharmaceutical industry, specializing in generics, biosimilars, and active pharmaceutical ingredients.
Overall Rating
4.0/5
based on 5.3k reviews
3% above
industry average
Highly rated for
Job security, Salary, Work-life balance
Work Policy
Work from office
88% employees reported
Monday to Saturday
59% employees reported
Strict timing
53% employees reported
No travel
44% employees reported
View detailed work policy
Top Employees Benefits
Job/Soft skill training
255 employees reported
Health insurance
244 employees reported
Office cab/shuttle
182 employees reported
Cafeteria
83 employees reported
View all benefits
About Aurobindo Pharma
Founded in1986 (39 yrs old)
India Employee Count10k-50k
Global Employee Count10k-50k
India HeadquartersHyderabad/Secunderabad, Telangana, India
Office Locations
--
Websiteaurobindo.com
Primary Industry
Other Industries
Are you managing Aurobindo Pharma's employer brand? To edit company information,
claim this page for free
View in video summary
Founded in 1986 by Mr. P.V. Ramprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born of a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry. Aurobindo Pharma became a public company in 1992 and listed its shares on the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillin’s, Aurobindo Pharma has a presence in key therapeutic segments such as neurosciences (CNS), cardiovascular (CVS), anti-retroviral, anti-diabetics, gastroenterology and Anti-biotics Through cost effective manufacturing capabilities and a few loyal customers, the company also entered the high margin specialty generic formulations segment. Today Aurobindo Pharma has evolved into a knowledge driven company manufacturing active pharmaceutical ingredients and formulation products. It is R&D focused and has a multi-product portfolio with manufacturing facilities in several countries.
Mission: Aurobindo’s mission is to become the most valued Pharma partner to the World Pharma fraternity by continuously researching, developing and manufacturing a wide range of pharmaceutical products that comply with the highest regulatory standards.
Vision: To build a leading global generic pharma company and become one of the top 10 by 2020.
Report error
Managing your company's employer brand?
Claim this Company Page for FREE
Brands of Aurobindo Pharma
Apis India
3.5
• 158 reviews
AuroZymes
3.0
• 1 review
ABECA - AmbitionBox Employee Choice Awards
Best of the best, rated by employees
Aurobindo Pharma won India’s Largest Employee Choice Awards in Large Companies Category.
Top Rated Pharma Company
Share
Aurobindo Pharma Ratings
based on 5.3k reviews
Overall Rating
4.0/5
How AmbitionBox ratings work?
5
2.5k
4
1.6k
3
636
2
239
1
335
Category Ratings
4.3
Job security
3.9
Salary
3.8
Work-life balance
3.7
Work satisfaction
3.6
Company culture
3.6
Skill development
3.5
Promotions
Aurobindo Pharma is rated 4.0 out of 5 stars on AmbitionBox, based on 5.3k company reviews. This rating reflects a generally positive employee experience, indicating satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at Aurobindo Pharma
based on 5.1k reviews
3.8
Rated by 245 Women
Rated 4.2 for Job security and 3.6 for Work-life balance
4.0
Rated by 4.8k Men
Rated 4.3 for Job security and 3.9 for Salary
Work Policy at Aurobindo Pharma
based on 499 reviews in last 6 months
Work from office
88%
Hybrid
7%
Permanent work from home
5%
Aurobindo Pharma Reviews
Top mentions in Aurobindo Pharma Reviews
+ 5 more
Compare Aurobindo Pharma with Similar Companies
 |  Change Company |  Change Company |  Change Company | |
|---|---|---|---|---|
Overall Rating | 4.0/5 based on 5.3k reviews | 4.0/5 based on 7.4k reviews | 4.1/5 based on 6.8k reviews | 4.1/5 based on 7.6k reviews |
Highly Rated for | Job security Salary Work-life balance | Skill development Salary Work-life balance | Salary Skill development Job security | Skill development Salary Work-life balance |
Critically Rated for |  No critically rated category | Promotions | No critically rated category | No critically rated category |
Primary Work Policy | Work from office 88% employees reported | Work from office 74% employees reported | Work from office 67% employees reported | Work from office 72% employees reported |
Rating by Women Employees | 3.8 Good rated by 245 women | 3.9 Good rated by 856 women | 4.0 Good rated by 516 women | 4.0 Good rated by 778 women |
Rating by Men Employees | 4.0 Good rated by 4.8k men | 4.0 Good rated by 6.2k men | 4.1 Good rated by 6k men | 4.1 Good rated by 6.5k men |
Job security | 4.3 Good | 3.5 Good | 3.9 Good | 3.7 Good |
View more
Aurobindo Pharma Salaries
Aurobindo Pharma salaries have received with an average score of 3.9 out of 5 by 5.3k employees.
Technical Assistant
(1.1k salaries)
Unlock
₹2.4 L/yr - ₹6.8 L/yr
Deputy Manager
(541 salaries)
Unlock
₹10.3 L/yr - ₹18.2 L/yr
Senior Technical Assistant
(320 salaries)
Unlock
₹4.1 L/yr - ₹8.2 L/yr
Research Associate
(277 salaries)
Unlock
₹2.8 L/yr - ₹8.1 L/yr
Executive Production
(217 salaries)
Unlock
₹3.1 L/yr - ₹8.1 L/yr
Senior Chemist
(169 salaries)
Unlock
₹3.3 L/yr - ₹7 L/yr
Scientist
(169 salaries)
Unlock
₹7.4 L/yr - ₹14.5 L/yr
Executive Engineer
(164 salaries)
Unlock
₹3 L/yr - ₹7.9 L/yr
Chemist
(144 salaries)
Unlock
₹2 L/yr - ₹5.6 L/yr
QA Executive
(139 salaries)
Unlock
₹3.4 L/yr - ₹8 L/yr
Aurobindo Pharma Interview Questions
Aurobindo Pharma Jobs
Popular Designations Aurobindo Pharma Hires for
Popular Skills Aurobindo Pharma Hires for
Current Openings
Aurobindo Pharma News
View all
31 Dividend Stocks: MCX, Indian Oil, Hindalco, Ceat, Mankind Pharma — Last Day To Buy Shares To Qualify
- Investors have until the last session on Thursday to buy shares of dividend stocks like MCX, Indian Oil, Hindalco, Ceat, Mankind Pharma, and others to qualify for receiving dividends before the ex/record date.
- Under India's T+1 settlement cycle, shares must be bought before the record date, like for MCX which offers a dividend of Rs 30 per share, Indian Oil with Rs 3 per share, Hindalco with Rs 5, and Ceat with Rs 30.
- Dividends serve as a reward for shareholders and can be annual, special, or interim. Other dividend stocks in focus include ABB India Ltd., Aurobindo Pharma Ltd., Paras Defence, and Space Technologies Ltd., and Quess Corp.
- The article is eligible for a web story as it provides valuable information about dividend stocks and the importance of buying shares before the ex/record date to receive dividends.
Bloomberg Quint | 7 Aug, 2025
Trump Tariff Impact: Textiles, Pharma, Oil & Gas, Electronic Equipment Face Threat
- US President Trump's 25% tariff on Indian exports can impact key industries like pharmaceuticals, textiles, auto components, chemicals, and energy.
- Auto and auto ancillary companies, including Sona BLW, Ramkrishna Forgings, Bharat Forge, and Tata Motors, with high exposure to the US face significant revenue risk.
- Pharmaceutical companies like Gland Pharma, Aurobindo Pharma, Dr. Reddy's, and others may experience significant earnings risk due to potential tariffs on Indian generics by the US.
- Textiles and garments, energy sector, solar, chemical companies, seafood exporters, and consumer goods companies are also vulnerable to the impact of the tariffs.
Bloomberg Quint | 31 Jul, 2025
Aurobindo Pharma to manufacture long-acting HIV treatment for global markets
- Aurobindo Pharma based in Hyderabad will manufacture and supply a long-acting injectable HIV treatment across 133 countries, including low- and middle-income markets.
- The treatment provides an alternative to daily pills by offering patients the option of receiving one injection every one or two months.
- ViiV Healthcare and the Medicines Patent Pool have updated their voluntary licensing agreement to include patents for a long-acting HIV treatment in compliance with updated WHO guidance.
- The aim is to increase access to long-acting HIV treatment in various countries worldwide, especially for those facing challenges with oral regimens.
HinduBusinessLine | 15 Jul, 2025
Stock Market Today: All You Need To Know Going Into Trade On May 29
- The Nifty 50 closed 73.75 points lower, and the BSE Sensex ended 239.31 points down on the recent trading day.
- Foreign portfolio investors bought stocks worth Rs 4,662.9 crore, while domestic institutional investors were net buyers of equities worth Rs 7,912 crore.
- Upcoming Nifty earnings include companies like Bajaj Auto, Alkem Laboratories, and Amara Raja Energy & Mobility, among others.
- Earnings post-market hours feature companies like Deepak Nitrite, Cummins India, Insecticides (India), and Bata India, with varying financial highlights and performance.
- Stocks in the news include IndusInd Bank, Infosys, Tata Chemicals, DLF, Grasim Industries, LTIMindtree, and Aurobindo Pharma, reflecting various corporate developments.
- Recent IPO offerings like Aegis Vopak Terminals, Schloss Bangalore, Prostarm Info Systems, and Scoda Tubes had varying subscription rates on different days.
- Insider trading activities of companies like Supreme Industries, Asahi India Glass, Usha Martin, and Voltamp Transformers were reported recently.
- Currency update reveals the Indian rupee weakened by 3 paise against the US dollar, closing at 85.37.
- Market observations included Nifty futures down by 0.46%, a decrease in Nifty May futures open interest, and notable open interest levels for Nifty Options May 29 Expiry.
- Trading tweaks, F&O cues, and the latest currency update provide insights into recent market activities and trends for investors and traders.
Bloomberg Quint | 29 May, 2025
Aurobindo Pharma Q4 Review: Well-Placed To Capture Market Opportunities, Says Motilal Oswal, Maintaining Buy
- Aurobindo Pharma exhibited slightly better-than-expected sales/Ebitda (2%/3% beat) for the quarter.
- Aurobindo Pharma delivered the highest-ever quarterly Ebitda in Q4 FY25, led by a higher offtake in the US generics segment and steady traction in the EU segment.
- Motilal Oswal reiterates Buy for Aurobindo Pharma's stock due to its attractive valuation of 16x FY26E EPS of Rs 73/14x FY27E EPS of Rs 83.5.
Bloomberg Quint | 28 May, 2025
Aurobindo Pharma Share Price Rises After Q4 Revenue Growth
- Aurobindo Pharma's share price rose over 2% after reporting a 10.6% year-on-year increase in consolidated revenue to Rs 8,382 crore in Q4 FY25.
- Despite a slight dip in net profit, the company's overall performance was boosted by revenue growth across its business segments.
- The US formulations segment revenue increased by 13.5% to Rs 4,072 crore, while the Europe formulations segment saw a rise of 17.2% year-on-year to Rs 2,147 crore.
- Analysts maintain a positive outlook on Aurobindo Pharma, with 23 out of 29 analysts tracking the company recommending a 'buy' rating, indicating an average 12-month consensus price target implying a 25.2% upside.
Bloomberg Quint | 27 May, 2025
Stock Market Live: GIFT Implies Muted Start; Aurbindo Pharma, KEC International, PTC India Shares In Focus
- Asian markets in Japan and South Korea show a decline as investors wait for trade updates and assess China's April industrial profit growth data.
- The GIFT Nifty was flat at 25,035.00, indicating a neutral start for the Nifty 50 index. Aurbindo Pharma, KEC International, PTC India shares will be in focus due to fourth-quarter earnings.
- Benchmark indices closed higher on Monday with NSE Nifty 50 up by 0.60% at 25,001 and BSE Sensex increased by 0.56% at 82,176 amid domestic market volatility.
- Key resistance areas for traders are predicted at 25,150–25,250/82500-82800, with support zones at 24,870/81900. Bullish sentiment is expected above the support level.
Bloomberg Quint | 27 May, 2025
Stock Market Today: All You Need To Know Before Going Into Trade On May 27
- The NSE Nifty 50 closed 148 points, or 0.60% higher at 25,001 and the BSE Sensex ended 455.37 points, or 0.56% up at 82,176.
- Foreign portfolio investors mopped up stocks worth Rs 136 crore, while domestic institutional investors stayed net buyers for the fifth straight day.
- Key earnings to watch include companies like Life Insurance Corporation of India, Bosch, ITI, NMDC, Procter & Gamble Hygiene and Health Care, among others.
- Post-market earnings highlights cover companies like Aurobindo Pharma, Brainbees Solutions, Hi-Tech Pipes, Schneider Electric, Shilpa Medicare, and Sumitomo Chemical.
- Stocks in the news include Garden Reach Shipbuilders & Engineers, InterGlobe Aviation, PG Electroplast, KEI Industries, and Thirumalai Chemicals, among others.
- IPO offerings like Aegis Vopak Terminals and Schloss Bangalore (Leela Hotels IPO) are subscribed partially, while Prostarm Info Systems is set to offer shares for bidding.
- In trading tweaks, price bands change, companies announce dividends, and Nifty May Futures and Options cues are observed along with currency update.
- The Indian rupee strengthened by 12 paise to close at 85.1 against the US dollar on Monday amid various global and domestic economic factors.
Bloomberg Quint | 27 May, 2025
Q4 Results Live: Gillette, KEC International, Blue Dart, Nazara Technologies In Focus
- Nearly 30 companies, including Gillette, KEC International, Blue Dart, and Nazara Technologies, are set to report their March-quarter results today.
- Other companies announcing their final quarter results today include Bayer CropScience, RateGain Travel Tech, and Olectra Greentech.
- Aurobindo Pharma is estimated to post a 9.4% increase in revenue, with projected Ebitda at Rs 1,826.5 crore and net profit at Rs 1,013 crore.
- Stay updated with NDTV Profit's live coverage of Q4 earnings for the latest updates on companies like Gillette, KEC International, Blue Dart, and Nazara Technologies.
Bloomberg Quint | 26 May, 2025
Stock Market Today: All You Need To Know Before Going Into Trade On May 26
- On Friday, NSE Nifty 50 closed 243.45 points higher, while BSE Sensex ended 769 points up.
- Foreign portfolio investors turned net buyers on Friday, purchasing Indian equities worth Rs 1,794.59 crore.
- Domestic institutional investors remained net buyers for the fourth consecutive day, buying equities worth Rs 299.78 crore.
- Key stocks to watch for earnings include Aurobindo Pharma, Blue Dart Express, and Maharashtra Seamless, among others.
- JSW Steel reported Q4 highlights with increased revenue, Ebitda, net profit, and capacity utilization achievements.
- Several companies announced earnings, including Balkrishna Industries, Glenmark Pharma, Reliance Infrastructure, and more.
- Stocks in the news: Bharti Airtel, TVS Srichakra, Lupin, Sun Pharma, and others shared updates on orders, investments, and developments.
- Bulk deals involved companies like Cartrade Tech, Gravita India, and Interarch Building Solutions, among others.
- IPO offerings from companies such as Belrise Industries, Aegis Vopak Terminals, and Schloss Bangalore were subscribed or set for bidding.
- Trading tweaks included price band changes, ex-dividend declarations, block deals, F&O cues, and a currency update on the Indian rupee.
Bloomberg Quint | 26 May, 2025
Powered by
Aurobindo Pharma Subsidiaries
Eugia Pharma Specialities
4.0
• 559 reviews
APL Healthcare
3.8
• 68 reviews
Auro Peptides
3.7
• 38 reviews
Silicon Life Sciences
4.3
• 7 reviews
Tergene Biotech
1.5
• 2 reviews
APL RESEARCH CENTRE
5.0
• 2 reviews
Report error
Aurobindo Pharma Offices
Compare Aurobindo Pharma with
Cipla
4.1
Dr. Reddy's
4.0
Sun Pharmaceutical Industries
4.1
Lupin
4.1
Zydus Lifesciences
4.0
Intas Pharmaceuticals
4.1
Hetero
3.8
Macleods Pharmaceuticals
3.6
Viatris
4.2
Alembic Pharmaceuticals
4.0
Abbott
4.1
Glenmark Pharmaceuticals
3.8
Ipca Laboratories
3.9
Alkem Laboratories
3.9
Mankind Pharma
3.8
Torrent Pharmaceuticals
3.9
MSN Laboratories
3.6
Ajanta Pharma
3.9
Akums Drugs & Pharmaceuticals Limited
4.3
GlaxoSmithKline Pharmaceuticals
4.1
Edit your company information by claiming this page
Contribute & help others!
You can choose to be anonymous
Companies Similar to Aurobindo Pharma
Cipla
Manufacturing, Pharma
4.1
• 7.6k reviews
Dr. Reddy's
Clinical Research, Pharma
4.0
• 7.4k reviews
Sun Pharmaceutical Industries
Healthcare / Pharma, Manufacturing, Analytics & KPO, Pharma
4.1
• 6.8k reviews
Lupin
Biotech & Life sciences, Manufacturing, Pharma
4.1
• 6.7k reviews
Zydus Lifesciences
Biotech & Life sciences, Pharma
4.0
• 6.6k reviews
Intas Pharmaceuticals
Biotech & Life sciences, Pharma
4.1
• 3.9k reviews
Hetero
Healthcare / Pharma, Clinical Research, Healthcare, Pharma
3.8
• 3.8k reviews
Macleods Pharmaceuticals
Biotech & Life sciences, Pharma
3.6
• 3.7k reviews
Viatris
Manufacturing, Pharma
4.2
• 3.5k reviews
Alembic Pharmaceuticals
Real Estate, Engineering & Construction, Biotechnology, Pharma
4.0
• 3.4k reviews
Abbott
Healthcare / Pharma, Media & Entertainment / Publishing, Pharma
4.1
• 3.3k reviews
Glenmark Pharmaceuticals
Pharma
3.8
• 3.2k reviews
Aurobindo Pharma FAQs
When was Aurobindo Pharma founded?
Aurobindo Pharma was founded in 1986. The company has been operating for 39 years primarily in the Pharma sector.
Where is the Aurobindo Pharma headquarters located?
Aurobindo Pharma is headquartered in Hyderabad/Secunderabad, Telangana.
How many employees does Aurobindo Pharma have in India?
Aurobindo Pharma currently has more than 26,000+ employees in India. Research & Development department appears to have the highest employee count in Aurobindo Pharma based on the number of reviews submitted on AmbitionBox.
Does Aurobindo Pharma have good work-life balance?
Aurobindo Pharma has a Work-Life Balance Rating of 3.8 out of 5 based on 5,200+ employee reviews on AmbitionBox. 77% employees rated Aurobindo Pharma 4 or above, while 23% employees rated it 3 or below on work-life balance. This indicates that the majority of employees feel a generally balanced work-life experience, with some opportunities for improvement based on the feedback. We encourage you to read Aurobindo Pharma work-life balance reviews for more details.
Is Aurobindo Pharma good for career growth?
Career growth at Aurobindo Pharma is rated fairly well, with a promotions and appraisal rating of 3.5. 77% employees rated Aurobindo Pharma 4 or above, while 23% employees rated it 3 or below on promotions / appraisal. Though the sentiment is mixed for career growth, majority employees have rated it positively. We recommend reading Aurobindo Pharma promotions / appraisals reviews for more detailed insights.
What are the pros and cons of working in Aurobindo Pharma?
Working at Aurobindo Pharma comes with several advantages and disadvantages. It is highly rated for job security, salary & benefits and work life balance. However, it is poorly rated for promotions / appraisal, skill development and company culture, based on 5,200+ employee reviews on AmbitionBox.
Stay ahead in your career. Get AmbitionBox app
Trusted by over 1.5 Crore job seekers to find their right fit company
85 Lakh+
Reviews
10L+
Interviews
4 Crore+
Salaries
1.5 Cr+
Users
Contribute to help millions
AmbitionBox Awards
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2025 Info Edge (India) Ltd.
Follow Us
